Peripheral blood stem cell transplantation in children with beta-thalassemia

Creative Commons License

YEŞILIPEK M. A., HAZAR V., Kupesiz A., KIZILORS A., UGUZ A., Yeğin O.

BONE MARROW TRANSPLANTATION, cilt.28, sa.11, ss.1037-1040, 2001 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 11
  • Basım Tarihi: 2001
  • Doi Numarası: 10.1038/sj.bmt.1703284
  • Dergi Adı: BONE MARROW TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1037-1040
  • Anahtar Kelimeler: peripheral blood stem cell transplantation, beta-thalassemia, children, MARROW-TRANSPLANTATION, ALLOGENEIC TRANSPLANTATION, BONE-MARROW, PBPC
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Fifteen patients with beta-thalassemia received an allogeneic peripheral blood stem cell transplant. Median age was 3.5 years (1-15 years). Six were class I, four class II and five class III according to the Pesaro criteria. All of the donors were HLA-phenotypically identical (13 siblings and two parents). Nine patients were given BU + CY and six BU + CY plus ATG as conditioning. All patients received MTX (+1, +3, +6) and CsA (9-12 months) post transplant for GVHD prophylaxis. The median neutrophil and platelet engraftment times were day 12 and day 16, respectively. cGVHD was observed in three patients. Two patients died. Thirteen patients are well, and transfusion-independent 2-30 months after PSCT. No recurrences of thalassemia have been seen. Overall and event-free survival were 86.6%. In conclusion, we suggest that PSCT can be considered a safe and effective treatment for children with beta-thalassemia.